Strides Arcolab announced that it received ANDA approval for Labetalol Hydrochloride or HCI injection of USP 100mg/20ml and 200mg/40 ml strengths. This is expected to be launched shortly.
Labetalol is the third product launched by the company in partnership with Sagent Pharmaceuticals. Under the partnership, both the companies are jointly developing, supplying and marketing more than 25 injectable products for the U.S market.
Labetalol HCI injection is contraindicated in bronchial asthma, overt cardiac failure, greater than first degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypo-tension, and in patients suffering from hypersensitivity to any component of the product.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.